TABLE 5.

Recurrence, metachronous head and neck cancer, and their treatment after transoral surgery

Local recurrence (n = 662 lesions)	53 (8.0%)
Treatment for recurrent lesions
Transoral surgery	39 (73.6%)
Traditional open surgery	5 (9.4%)
With laryngectomy	3 (5.7%)
Without laryngectomy	2 (3.8%)
Observation	3 (5.7%)
Definitive chemoradiotherapy	2 (3.8%)
Radiotherapy	2 (3.8%)
Argon plasma coagulation	1 (1.9%)
Laser ablation	1 (1.9%)
Regional lymph node recurrence (n = 568 patients)	26 (4.6%)
Location of recurrent lesions
Only same side	20 (76.9%)
Only opposite side	2 (7.7%)
Both sides	2 (7.7%)
Unknown	2 (7.7%)
Treatment for recurrent lesions
Neck dissection	15 (57.7%)
Neck dissection + postoperative chemotherapy	3 (11.5%)
Neck dissection + postoperative radiotherapy	3 (11.5%)
Neck dissection + postoperative chemoradiotherapy	2 (7.7%)
Definitive chemoradiotherapy	3 (11.5%)
Distant recurrence (n = 568 patients)	3 (0.5%)
Location of recurrent lesions
Lung	2 (66.7%)
Lung + Liver	1 (33.3%)
Treatment for recurrent lesions
Chemotherapy	1 (33.3%)
Observation	2 (66.7%)
Metachronous head and neck cancer (n = 568 patients)	132 (23.2%) with 234 lesions
Treatment for metachronous lesions
Transoral surgery	207 (88.5%)
Traditional open surgery	5 (2.1%)
With laryngectomy	1 (0.4%)
Without laryngectomy	4 (1.7%)
Argon plasma coagulation	9 (3.8%)
Radiotherapy	6 (2.6%)
Observation	3 (1.3%)
Definitive chemoradiotherapy	1 (0.4%)
Chemotherapy	1 (0.4%)
Unknown	2 (0.9%)